A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
Status:
COMPLETED
Trial end date:
2024-12-11
Target enrollment:
Participant gender:
Summary
The primary objective of the study is:
• To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in healthy participants.